Trial Profile
The effect of ipraglifozin on circadian rhythm in blood glucose using CGM in type 2 diabetes
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Aug 2016
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 21 Jul 2016 Status changed from recruiting to discontinued.
- 14 Jul 2014 New trial record